TSBL-based vs BMI-based limb length in one-anastomosis gastric bypass

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with morbid obesity undergoing one-anastomosis gastric bypass are randomized to have the biliopancreatic limb length determined by total small bowel length or by BMI-based fixed lengths. In the TSBL-based method, the limb length is 0.35 times the measured TSBL, while the BMI-based method uses fixed lengths (150, 180, or 200 cm). Primary outcome is percent excess weight loss (%EWL) over 12 months, with secondary outcomes including %TWL, BMI changes, comorbidity improvement, and complication rates. The study uses objective measurements and linear mixed models to analyze group, time, and group-time effects, and is conducted at a single center in Almaty, Kazakhstan. Blinding was not possible due to the surgical nature of the intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age between 18 and 65 years
* BMI ≥35 kg/m² in non-Asian populations or ≥32.5 kg/m² in Asian populations
* Presence or absence of metabolic comorbidities (including type 2 diabetes, hypertension, and dyslipidaemia)
* Eligibility for primary one-anastomosis gastric bypass (OAGB)
* Provision of written informed consent

Exclusion Criteria:

* BMI below the defined thresholds
* Severe decompensated cardiac, pulmonary, hepatic, or renal disease
* Acute inflammatory conditions
* Active gastric or duodenal ulcer
* Psychiatric disorders or substance abuse
* Pregnancy or breastfeeding
* Active malignancy
* Severe intra-abdominal adhesions due to prior surgery
* Secondary obesity related to hypothalamic-pituitary-adrenal axis disorders

Where it's running

• JSC "National Scientific Center of Surgery named after A.N. Syzganov"
  Almaty, Kazakhstan Recruiting

Study contacts

• Study coordinator: Nurbol Orynbassar
• Email: nurbolorynbassar@gmail.com
• Phone: +77474528797

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.